A B S T R A C T Proteolytic enzymes are associated with normal and neoplastic tissues. Therefore protease inhibitors might also be involved in the control of cell function. a1-protease antigen and antitryptic activity have been found in normal and neoplastic human ovarian homogenate. The inhibitor has been localized to ovarian stromal cells or tumor cells by immunoperoxidase staining. The protein was purified to apparent homogeneity as judged by alkaline gel and sodium dodecyl sulfate (SDS) gel electrophoresis. Immunochemical studies revealed antigenic similarity to plasma a,-protease inhibitor by double immunodiffusion and similar mobility on immunoelectrophoresis and two-dimensional electroimmunodiffusion. The molecular weight was similar to that described for plasma a,-protease inhibitor: 60,000 by gel filtration and 53,500 by SDS electrophoresis. Furthermore, the phenotypic pattern as deterrnined by acid starch gel electrophoresis and immunoprecipitation was PiMM, which is the predominant genetic variant in normal plasma a,-protease inhibitor. An inhibitor was isolated and purified from an ovarian carcinoma that exhibited functional, immunochemical, and physical similarity to the normal ovarian a1-protease inhibitor. a1-protease inhibitor from normal and malignant ovaries competitively inhibited bovine pancreatic trypsin at incubation times of 5 (1) , chymotrypsin (1) , elastase (2) , collagenase (3) , and renin (4) . The importance of a1-protease inhibitor in human disease is indicated by the observation that its deficiency is associated with pulmonary emphysema (5, 6) and liver disease (7, 8) . Direct and indirect evidence suggests that the liver is the site of synthesis of the plasma a,-protease inhibitor (9) (10) (11) (12) . However, the action of this inhibitor is directed primarily toward tissue rather than plasma proteolytic enzymes, suggesting that it might also be synthesized in cells and tissue aside from the liver. The occurrence of a,-protease inhibitor in extrahepatic sites may be important, since certain protease inhibitors inhibit the growth of tumor cells (13, 14) or the process of transformation (15) . Thus, the increased level of protease activity in malignant cells (16, 17) might be due to a deficiency of protease inhibitors in these cells. In addition, the role of proteolysis in such physiological events as ovulation (18) , suggests that inhibitory function might exist for tissue a1-protease inhibitor, were it present.
In this study ovarian Finally, the occurrence of this inhibitor in the ovary invites future exploration of its role in ovulation.
METHODS
Ovary procurement. Three normal, one polycystic, and five malignant ovaries were obtained from nine patients during surgery. A representative portion was removed and fixed in Bouin's solution, dehydrated, and embedded in paraffin blocks. Sections from all nine were used for hematoxylin and eosin staining and for immunoperoxidase studies for a,-protease inhibitor (see below). Three ovaries were selected for in depth study of the a,-protease inhibitor. One was a normal postmenopausal ovary without follicles (B.L.), the second a polycystic ovary with multiple follicles (A.S.), and the third was a mucinous cystadenocarcinoma containing no follicles (G.B.). These were used for preparation oftissue homogenates for isolation of a,-protease inhibitors.
Immunocytochemical techniques. Immunoperoxidase reactions for a1-antitrypsin were tested on unstained, deparaffinized, and hydrated 6 um sections, by using commercially available reagents (see "Antisera") and briefrinses with 0.1 M sodium phosphate buffer pH 7.4 containing 0.15 M NaCl (PBS)l between steps, in a three-layered immunoenzyme bridge technique with unlabeled antibody and soluble peroxidase-antiperoxidase complex (19 (e) 3,3'-diaminobenzidine/hydrogen peroxide solution, prepared immediately before use, by dissolving 5 mg of diaminobenzidine in 10 ml of 0.05 M Tris HCI buffer, pH 7.2, then adding four to five drops of 3% H202, 5-10 min; followed by counterstaining, dehydration, permanent mounting, and examination by light microscopy (20) .
The specificity of the primary antiserum was tested before use by double diffusion (21) . For Enzymes. Bovine pancreatic trypsin (crystallized three times) treated with tosylphenylalanylchloromethyl ketone to render it free of chymotryptic activity was obtained from Worthington Biochemical Corp., Freehold, N. J. Plasminogen was prepared by affinity chromatography (22) or was purchased from Kabi, Stockholm, Sweden. Both preparations of plasminogen gave similar results. Varidase (Lederle Laboratories, Div. American Cyanamid Co., Pearl River, N. Y.) was the source of streptokinase. Human plasma kallikrein was prepared in our laboratory by alcohol and salt fractionation and ion exchange chromatography and was futher purified by gel filtration (23) . Urokinase was obtained from CalbiochemBehring Corp., American Hoechst Corp., San Diego, Calif.
Antisera. Antibodies prepared in rabbits against human plasma proteins, anti-al-antitrypsin, anti-inter-a-trypsin inhibitor, anti-a2-macroglobulin, anti-Cl inhibitor, anti-thrombin III, anti-transferrin, and anti-haptoglobin were obtained from Behring Diagnostics, Somerville, N. J. Anti-a2 plasmin inhibitor was a gift from Dr. Aoki of Jichi Medical School, Japan. Peroxidase conjugated to anti-rabbit gamma globulin and goat anti-rabbit IgG were purchased from N. L. Cappel Laboratories, Cochranville, Pa. Column chromatography and gel filtration. QAE and G-200 Sephadex and DEAE-cellulose were equilibrated with the starting buffer according to the directions of the manufacturer, and were packed into columns by gravity. A standard curve was constructed to estimate molecular weights by gel filtration. The following proteins were used: human y-globulin, bovine serum albumin, ovalbumin, and a-chymotrypsinogen. Sephadex G-200 filtration was carried out using a downward flow column (1.6 x 86.5 cm) at a constant operating pressure of40 cm. Samples of up to 2% ofthe column volume were applied. The flow rate was 8 ml/h. Affinity chromatography. To remove albumin from purified inhibitor, a Con A-Sepharose column was used. A small column (2 ml vol) was packed and equilibrated with 0.01 M acetate buffer at pH 6.5 containing 0.2 M NaCl, 1 mM of each CaCl2 and MnCl2. Inhibitor samples containing <10 mg total protein were passed through the resin at 4°C. After the removal of the unabsorbed proteins by the starting buffer, the inhibitor was eluted from the Con A-Sepharose with a 0. 1-M solution of a-methyl-D-glucoside in the 0.05 M Tris buffer. 1-ml fractions were collected and assayed for trypsin inhibition. For functional studies, fractions containing the inhibitor were pooled and stabilized with bovine serum albumin 100 ,ug/ml before concentration. The recovery of inhibitor is generally -75% based on the total trypsin inhibitory capacity of the material applied to the column.
Gel electrophoresis. Analytical polyacrylamide disc gel electrophoresis was performed according to Davis (24) . Sam (26) . Lysosomes were further purified from the light mitochondria by sucrose density gradient centrifugation (27) . To Laurell (30) with minor modifications. a-protease inhibitor phenotyping was carried out according to Fagerhol and Laurell (31) .
Preparation of immobilized trypsin. Sepharose4B was activated by cyanogen bromide and coupled to bovine trypsin by the method ofCuatrecases (32) as previously described (33) . Trypsin (100 mg) in 25 ml of 0. 1 M sodium bicarbonate, pH 8.9, was added to the activated agarose slurry containing 40 ml resin and 25 ml of the above buffer. The concentration ofactive trypsin in solution or bound to agarose was determined by the active site titration method of Chase and Shaw (34) . Approximately 1 mg trypsin was linked to each milliliter of resin.
Inhibition of trypsin amidase activity. Inhibition by cell components was determined by measuring the degree of hydrolysis using a tripeptide p-nitroanilide substrate. Up to 0.30 ml of sample from different stages of purification was mixed with 0.05 M Tris imidazole buffer, pH 8.1, containing 0.1 M NaCl and 0.5 mg/ml bovine serum albumin (in a total volume of 0.9 ml), and 0.01 ml of trypsin (0.3 jig). The mixture was incubated at 30°C for 5 min unless otherwise stated. At the end ofthe incubation period, 0.1 ml of 1 mM substrate Bz-Pro-ValArg-pNA was added and incubated for 2 min. The reaction was stopped by the addition of 0.1 ml glacial acetic acid and the color formed measured at 405 nm with a Gilford 240 spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, Ohio). The blanks did not contain trypsin and the control contained buffer instead of sample.
Inhibition of trypsin proteolytic activity. A mixture of up to 0.3 ml 0.1 M phosphate buffer at pH 7.65, 0.01 ml trypsin (0.3 ,ug), and bovine serum albumin at a final concentration of 0.5 mg/ml was incubated for 4 min at 30°C. The degree of hydrolysis of casein and the extent of the inhibition were determined according to the method of Alkjaersig et al. (35) .
Inhibitor units. Hydrolysis of Bz-Pro-Val-Arg-pNA and H-D-Val-Leu-Lys-pNA was linear for at least 3 min under the experimental conditions. In the trypsin or plasmin amidase assays, when the remaining enzymes' activity was plotted on a semilog graph against the concentration of the inhibitor, a linear relationship was obtained. Therefore, we arbitrarily chose 1 U of inhibitor to be equal to that amount that could inhibit 50% of trypsin (0.30 ,g) or plasmin (0.05 casein units) activity.
Inhibition of plasmin amidase activity. The tripeptide substrate, H-D-Val-Leu-Lys-pNA was used. Up to 0.3 ml of inhibitor source was mixed with 0.05 M Tris-Cl buffer at pH 7.4, containing 1 mg/ml bovine serum albumin in a total volume of 0.9 ml; and 0.01 ml of plasmin (0.05 casein units). After incubation ofthe mixture for 5 min, 0.1 ml ofthe substrate (3 mM) was added and further incubated for 3 min. The reaction was stopped by the addition of0.1 ml of50% glacial acetic acid and the color formed measured at 405 nm. The blanks did not contain plasmin and the controls contained buffer instead of sample.
Affinity chromatography of trypsin inhibitors. To selectively isolate trypsin inhibitors, soluble fraction or lysosomal content from various tissues were exposed to trypsin-sepharose columns (36) i FIGURE 1 Immunocytochemical localization of a1-antitrypsin in ovaries by indirect peroxidaseantiperoxidase procedure. All frames are light micrographs. Frame A establishes the specificity of the antibody and peroxidase reaction by showing the absence of reaction product when normal rabbit serum was substituted for specific antibody in the primary step. This was used as a control for all ovaries examined. Note the absence of reaction product from stromal cells whereas faint reaction product is present in vessels indicating the presence of endogenous peroxidase in the blood cells, x400. Frames B-F show the distribution ofdense (dark) reaction product which corresponds to distribution of a,-antitrypsin antigen when specific a,-antitrypsin antibody was used in 284 Bagdasarian To study the electrophoretic mobilities of a1-protease inhibitor from various sources, soluble fractions from normal ovary (A.S.) and ovarian carcinoma (G.B.) were compared to plasma a1-protease inhibitor by immunoelectrophoresis (Fig. 3) . A similar mobility to plasma a1-protease inhibitor (B) was found for neoplastic (A) and normal (C) ovary when monospecific antiserum against a1-protease inhibitor I and II were used.
Functional localization of trypsin inhibitors. Subcellular fractions from normal (A.S.) and malignant (G.B) ovary were tested for trypsin inhibition using peptide substrate (Bz-Phe-Val-Arg-pNA). Trypsin inhibitory activity was present mainly in the soluble fraction (80% of the total activity). Lysosomal and membrane fractions contained 11.2 and 8.4% of the total activity. About 75% of the antitrypsin activity in the soluble fractions was located in the 50-80% saturation precipitate of ammonium sulfate and the remaining 25% of the activity was in the 25-50% saturation fraction. The homogenate and subcellular fractions of normal and malignant ovaries (80-100 ,ug total protein) were tested for urokinase inhibition. No inhibitory activity was found. The soluble fractions of normal and malignant ovaries revealed low levels of antiplasmin activity using H-D-Val-Leu-Lys-pNA. This activity is precipitated by ammonium sulfate at 25-50% saturation.
Purification of a,-protease inhibitor. Since the major portion of cellular a,-protease inhibitor was found in the soluble fraction, this fraction was used as the source for the a1-protease inhibitor purification. The normnal ovary obtained from B.L. was fractionated as described in Methods. The a,-protease inhibitor was localized in soluble and membrane fractions, while the antitrypsin activity was also present in the lysosomes. following the salt gradient, coincident with the a,-protease inhibitor antigen peak. Fractions indicated by the bar, containing the inhibitory activity and the a,-protease inhibitor antigen were pooled, concentrated, and gel filtered through a Sepharose4B column (Fig. 5) . A single peak oftrypsin inhibitor activity that also demonstrated a1-protease inhibitor antigen (not shown) was located in a region corresponding to -60,000 mol wt. When fractions were tested for human plasmin inhibition using H-D-Val-Leu-Lys-pNA peptide substrate, a small but distinct inhibitory activity was found under the antitrypsin peak. Alkaline disc gel analysis of the Sepharose4B peak revealed several contaminating proteins including one with similar mobility to a,-glycoprotein. Therefore, this material was further purified by chromatography on DE-52 cellulose at pH 6.5 (37) . Results of the chromatography are summarized in Fig. 6 . After removal of the unadsorbed proteins, the antitrypsin activity was eluted by applying a linear salt gradient (arrow) up to 0.2 M NaCl. Fractions containing the antitrypsin activity were pooled, concentrated, and dialyzed against 0.01 M Na-acetate buffer at pH 6.5 containig 0.2 M NaCl, 1 mM CaCl2, and 1mM MgCl2.
To remove the major contaminant albumin, the sample was passed through Con A-Sepharose equilibrated with the above acetate buffer (Fig. 7) . After complete removal of the unadsorbed proteins by the starting buffer, the a1-protease inhibitor was eluted by 0.1 M a-Dmethyl-glucoside in a single symmetrical peak corresponding to a discrete protein peak. Similar procedures were applied for the purification of a1-protease inhibitor from the ovarian carcinoma. No major differences were noted in the chromatographic patterns compared to normal ovary. The entire purification is summarized in Table I for both normal and malignant ovaries. On the basic of trypsin inhibitory activity an overall purification of 16- To demonstrate the homogeneity of the preparation, three criteria were chosen. An alkaline disc gel electrophoresis of highly purified preparation of a,-protease inhibitor (Fig. 8) obtained from normal and malignant ovaries revealed a single major protein band. The pro- Fig. 5 (vol/vol) a,-protease inhibitor antiserum immediately after disc gel electrophoresis and the proteins were subjected to electrophoresis into the second dimension. The rockets formed (Fig. 8) correspond to the region of the gels where the major protein bands migrated. In the normal ovary (Fig. 8A ) the rocket was symmetrical, but in the ovarian carcinoma (Fig. 8B ) a slower migrating shoulder appeared in front of the main rocket suggesting microheterogeneity. Analysis of the phenotype of the purified a,-protease inhibitor revealed a normal (PiMM) pattern for both normal and malignant ovaries. Both the normal and malignant ovaries show a major band on sodium dodecyl sulfate gel electrophoresis corresponding to a molecular weight of 53,500 (Fig. 9 ). 
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FIGURE 9 Sodium dodecyl sulfate gel electrophoresis of the highly purified a,-protease inhibitor. Preparations obtained from concanavalin A-Sepharose were used. The total proteins used were 5-,ug for a,-protease inhibitor from normal ovary (gel 1) and 4 ,ug for a1-protease inhibitor from ovarian carcinoma (gel 2). DISCUSSION a1-Protease inhibitor was identified immunohistochemically in epithelial, stromal and tumor cells of nine ovaries from nine patients by the use of specific antia,-protease inhibitor antibody and the indirect peroxidase method. The interstitial space in the ovaries was essentially free of reaction product. Protease inhibitor from three ovaries was isolated, purified, and studied for its molecular, antigenic, and inhibitory activity.
Using the soluble fraction of the ovarian cell homogenates as a source of a1-protease inhibitor, purification by ion exchange chromatography, gel filtration, and lectin affinity chromatography resulted in a preparation that revealed a singel band on polyacrylamide disc gel electrophoresis in the presence and absence of sodium dodecyl sulfate. Crossed immunoelectrophoresis demonstrated that this protein band was identical to the a,-protease inhibitor antigen in plasma. Although a,-protease inhibitor from normal and malignant cells were similar in migration, a slower migrating shoulder was evident in the preparations of the a1-protease inhibitor from malignant tissue. The similarity to plasma a1-protease inhibitor is further supported by the finding of a normal phenotype (PiMM). The molecular weight of normal and malignant ovarian a1-protease inhibitor as determined by gel filtration (60,000) and sodium dodecyl sulfate-gel electrophoresis (53,500) were in agreement with those reported for a1-protease inhibitor from plasma (38, 39) and platelets (33) .
Kinetics oftrypsin inhibition by highly purified ovarian a1-protease inhibitor was competitive in nature similar to the inhibition of trypsin by platelet a,-protease inhibitor and renin by plasma a1-protease inhibitor (4).
This study clearly established that a,-protease activity is present in the cells ofnormal and malignant ovaries. However, the evidence presented does not distinguish between synthesis by ovarian tissue or endocytosis of a1-proteinase inhibitor by ovarian cells. The presence of a1-protease inhibitor in the stromal cells of ovaries may be important in ovulation since stromal cells as well as the epithelial (so-called germinal) cells participate in the maturation of follicles, production of estrogen and formation of the corpus luteum. Although the mechanism of rupture ofthe mature follicle is not fully understood, proteolytic enzymes may play a role. Plasminogen activator has been shown to be involved in ovulaa1-Protease Inhibitor from Ovarytion (40) . Other enzymes have been isolated from sea urchin eggs (41) including a homogenous enzyme similar to bovine trypsin in its molecular weight and susceptibility to inhibitors diisopropylfluro-phosphate and soybean trypsin inhibitor (42) . The presence of the a,-protease inhibitor in ovarian tissue might serve to prevent extensive autodigestion of the tissue by tryptic enzymes following ovulation.
The number of samples examined in detail in this study was too small to allow comparison of the level of a,-protease inhibitor in normal and malignant ovarian cells. However, several studies suggest that inhibitor levels might be important, since increased protease activity is associated with transformation and uncontrolled proliferation (43) (44) (45) (46) . Cancerous tisstues of the bladder contained significantly higher levels of the mammalian cellular protease inhibitors, urokinase inhibitor and tissue plasminogen activator inhibitor than normal mucosa (47) . Ascitic fluid from patients with ovarian carcinoma contain much higher levels of trypsin inhibitors compared to ascitic fluid from patients with benign ovarian tumors (48) . However, whether any of these inhibitory activities were due to a1-protease inhibitor is not known. a,-protease inhibitor has been demonstrated by immunoflorescence in sections of tumor tissue in patients with endodermal sinus tumors (49, 50) , but a quantitative comparison with comparable normal tissue is not available. a,-protease inhibitor is also synthesized by a human hepatoma cell line (51) .
The presence of relatively high levels of a,-protease inhibitor in normal ovarian tissue and in malignant ovaries suggests that this inhibitor may be involved in the regtulation of proliferation in normal and malignant tissues.
